Update on anti-phospholipid antibodies in SLE: The Hopkins Lupus Cohort

Research output: Contribution to journalArticle

Abstract

Anti-phospholipid antibodies are common in patients in the Hopkins Lupus Cohort: 47% have anti-cardiolipin, 32.5% anti-β2-glycoprotein I and 26% lupus anticoagulant (by dRVVT confirmatory testing). Systemic lupus erythematosus patients with the lupus anticoagulant at baseline have a 50% chance of a deep venous thrombosis/pulmonary embolus in the next 20 years. Anti-phospholipid antibodies differ in their association with thrombosis: the lupus anticoagulant is most strongly associated with arterial and venous thrombosis and is the only anti-phospholipid antibody associated with myocardial infarction. Anti-phospholipid antibodies are not associated with atherosclerosis.

Original languageEnglish (US)
Pages (from-to)419-423
Number of pages5
JournalLupus
Volume19
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Lupus Coagulation Inhibitor
Anti-Idiotypic Antibodies
Phospholipids
Venous Thrombosis
Cardiolipins
Embolism
Systemic Lupus Erythematosus
Atherosclerosis
Glycoproteins
Thrombosis
Myocardial Infarction
Lung

Keywords

  • Anti-cardiolipin antibodies
  • Anti-phospholipid syndrome
  • Lupus anticoagulant

ASJC Scopus subject areas

  • Rheumatology

Cite this

Update on anti-phospholipid antibodies in SLE : The Hopkins Lupus Cohort. / Petri, Michelle.

In: Lupus, Vol. 19, No. 4, 04.2010, p. 419-423.

Research output: Contribution to journalArticle

@article{12ac36f146a446ad87b8c91e9bea433f,
title = "Update on anti-phospholipid antibodies in SLE: The Hopkins Lupus Cohort",
abstract = "Anti-phospholipid antibodies are common in patients in the Hopkins Lupus Cohort: 47{\%} have anti-cardiolipin, 32.5{\%} anti-β2-glycoprotein I and 26{\%} lupus anticoagulant (by dRVVT confirmatory testing). Systemic lupus erythematosus patients with the lupus anticoagulant at baseline have a 50{\%} chance of a deep venous thrombosis/pulmonary embolus in the next 20 years. Anti-phospholipid antibodies differ in their association with thrombosis: the lupus anticoagulant is most strongly associated with arterial and venous thrombosis and is the only anti-phospholipid antibody associated with myocardial infarction. Anti-phospholipid antibodies are not associated with atherosclerosis.",
keywords = "Anti-cardiolipin antibodies, Anti-phospholipid syndrome, Lupus anticoagulant",
author = "Michelle Petri",
year = "2010",
month = "4",
doi = "10.1177/0961203309360541",
language = "English (US)",
volume = "19",
pages = "419--423",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Update on anti-phospholipid antibodies in SLE

T2 - The Hopkins Lupus Cohort

AU - Petri, Michelle

PY - 2010/4

Y1 - 2010/4

N2 - Anti-phospholipid antibodies are common in patients in the Hopkins Lupus Cohort: 47% have anti-cardiolipin, 32.5% anti-β2-glycoprotein I and 26% lupus anticoagulant (by dRVVT confirmatory testing). Systemic lupus erythematosus patients with the lupus anticoagulant at baseline have a 50% chance of a deep venous thrombosis/pulmonary embolus in the next 20 years. Anti-phospholipid antibodies differ in their association with thrombosis: the lupus anticoagulant is most strongly associated with arterial and venous thrombosis and is the only anti-phospholipid antibody associated with myocardial infarction. Anti-phospholipid antibodies are not associated with atherosclerosis.

AB - Anti-phospholipid antibodies are common in patients in the Hopkins Lupus Cohort: 47% have anti-cardiolipin, 32.5% anti-β2-glycoprotein I and 26% lupus anticoagulant (by dRVVT confirmatory testing). Systemic lupus erythematosus patients with the lupus anticoagulant at baseline have a 50% chance of a deep venous thrombosis/pulmonary embolus in the next 20 years. Anti-phospholipid antibodies differ in their association with thrombosis: the lupus anticoagulant is most strongly associated with arterial and venous thrombosis and is the only anti-phospholipid antibody associated with myocardial infarction. Anti-phospholipid antibodies are not associated with atherosclerosis.

KW - Anti-cardiolipin antibodies

KW - Anti-phospholipid syndrome

KW - Lupus anticoagulant

UR - http://www.scopus.com/inward/record.url?scp=77951233843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951233843&partnerID=8YFLogxK

U2 - 10.1177/0961203309360541

DO - 10.1177/0961203309360541

M3 - Article

C2 - 20353980

AN - SCOPUS:77951233843

VL - 19

SP - 419

EP - 423

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 4

ER -